Heavy menstrual bleeding, pelvic pressure, and infertility are the main clinical manifestations linked to uterine fibroids. Hormonal contraceptives, including coformulated estrogen and progestin oral contraceptives, progestin-only birth control pills, and long-lasting levonorgestrel-releasing intrauterine system, have long been used to manage heavy menstrual bleeding (menorrhagia), but they do not reduce fibroid tumor volume or resolve bulk symptoms. During the forecast period, launches of novel selective progesterone receptor regulators (SPRMs) and gonadotropin-releasing hormone (Gn-RH) antagonists will provide more efficacious medical alternatives over procedures such as hysterectomy and myomectomy in the long-term management of uterine fibroids.
- Uterine fibroids commonly affect women in reproductive ages. How large are total prevalent uterine fibroids populations in the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom)?
- What percentage of patients were diagnosed in 2016? What percentage of diagnosed uterine fibroid patients received drug treatment in 2016? How will these rates change in 2026?
- We forecast that by 2024, three SPRMs will be approved for symptomatic uterine fibroids. How will three emerging SPRMs be differentiated and positioned in the uterine fibroids market?
- Which emerging SPRM will enjoy the greatest clinical and commercial success by 2026?
- We expect that three Gn-RH antagonists will be launched in the first half of our study period. What clinical role will second-generation, oral Gn-RH antagonist therapies play in the management of uterine fibroids?
- What are clinical advantages of Gn-RH antagonists compared with Gn-RH agonists, in the long-term and preoperative management of symptomatic uterine fibroids?
Primary research: Six country-specific interviews with uterine fibroids specialists (gynecologists, one radiologist, and one gynecological pathologist).
Epidemiology: Total prevalent cases of uterine fibroids by country, diagnosed and drug-treated cases.
Emerging therapies: Phase III/PR: 4; Phase II: 3; coverage of select preclinical and Phase I products.
Market forecast: Drug-level sales and patient share of key uterine fibroids therapies in 2026. Sales and patient share of ulipristal in the EU5 in 2016.
- Gedeon Richter
- Bayer HealthCare
Drugs: ulipristal, telapristone, vilaprisan, elagolix, relugolix, OBE-2109, leuprolide